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Abstract: Objective: To investigate the relationship between function and disease activity in early inflammatory arthritis 
(EIA). 
Methods: Canadian Early Arthritis Cohort (CATCH) (n=1143) is a multi-site EIA cohort. Correlations between the Health 
Assessment Questionnaire Disability Index (HAQ) and DAS28 were done at every 3 months for the first year and then at 
18 and 24 months. We also investigated the relationship between HAQ and DAS28 by age (<65 versus 65) and RF 
(positive vs negative). 
Results: Mean HAQ and DAS28 scores were highest at the initial visit with HAQ decreasing over 24 months from a 
baseline of 0.94 to 0.40 and DAS28 scores decreasing from 4.54 to 2.29. All correlations between HAQ and DAS28 were 
significant at all time points (p<0.01). The correlations between HAQ and DAS28 were variable over time. The strongest 
correlation between HAQ and DAS28 occurred at initial visit (most DMARD naive) (n=1,143) and 18 months (r=0.57, 
n=321) and 24 months (r=0.59, n=214). The baseline correlation between HAQ and DAS28 was significantly different 
than correlations obtained at 3, 6, and 12 months (p=0.02, 0.01, and 0.01, respectively). Age did not change the 
association between HAQ and DAS28 {<65 years old (r=0.50, n=868) versus 65 (r=0.48, n=254), p=0.49}. The 
correlation between HAQ and DAS28 was stronger with RF+ patients (r=0.63, n=636) vs RF negative (r=0.47, n=477), 
p=0.0043 
Conclusion: Over 2 years in EIA, HAQ and DAS both improved; correlations at time points were different over 2 years 
and RF status affected the correlations. 
Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal. 
SIGNIFICANT FINDINGS 
1. The relationship between DAS and HAQ in early 
inflammatory arthritis is strongest at first visit to an 
ERA clinic but varies even in follow-up over 3 
months to 2 years. 
 
 
*Address correspondence to this author at the 268 Grosvenor St., London, 
ON N6A 4V2 Canada; Tel: 519 646 6332; Fax: 519 646 6334;  
E-mail: janet.pope@sjhc.london.on.ca 
 
§This study has been presented as an abstract at ACR and Canadian 
Rheumatology Association meeting. 
2. The relationship between DAS and HAQ varies by 
age and RF status. 
INTRODUCTION 
 Rheumatoid arthritis (RA) is a chronic autoimmune 
inflammatory disease that can result in progressive joint 
damage and significant functional impairment [1]. Disease-
modifying anti-rheumatic drugs (DMARDs) have been 
shown to slow disease progression more effectively with 
early intervention than when started in more advanced 
disease, thus illustrating the importance of identifying RA 
early in its disease course [2-4]. With the recent publication 
DAS and HAQ in ERA The Open Rheumatology Journal, 2013, Volume 7   59 
of the 2010 ACR/EULAR criteria for RA, a new 
classification system now exists that identifies earlier stages 
of disease activity rather than relying on its late-stage 
features [5]. Earlier diagnosis will enable earlier 
implementation of disease-suppressing therapy to prevent or 
minimize undesirable disease sequelae, and has been shown 
to improve long-term outcomes particularly when combined 
with tighter control strategies (i.e. targeting to achieve 
disease remission or low disease activity states) [6]. 
 The objective of this study was to investigate the 
relationship between disease activity and functional capacity 
in early inflammatory arthritis (EIA) using data collected 
from the Canadian Early Arthritis Cohort (CATCH). Disease 
activity was assessed using the Disease Activity Score 
(DAS28), while functional capacity was determined using 
the Health Assessment Questionnaire Disability Index 
(HAQ). Our goal was to determine correlations between 
HAQ and DAS28 scores over time in EIA using a 
contemporary cohort where the amount of joint damage 
would be substantially less than a prevalent RA cohort and 
possibly less than historical RA cohorts due to earlier 
diagnosis and institution of DMARD therapy. We also 
investigated the relationship between HAQ and DAS28 in 
older and younger subjects and in those who were RF 
positive or negative to determine the effects of age and RF 
status on this relationship. 
 Due to the inconsistency of the correlations that have 
been made in the past, our goal was to clarify the 
relationship between disease activity and functional capacity 
with particular focus on the early stages of inflammatory 
arthritis. Through comparison of correlations between HAQ 
and DAS28 at different stages in EIA (namely, 0, 3, 6, 9, 12, 
18, and 24 months), we sought to determine how tightly 
these outcome measures were connected in a population with 
a relatively short duration of symptoms who had not yet 
accrued significant joint damage. This could provide a 
clearer understanding of overall health status and functional 
outcome in patients with early rheumatoid arthritis and how 
the relationship varies over time. 
METHODS 
Subjects 
 Data was collected from patients (n=1,143) enrolled into 
the Canadian Early Arthritis Cohort (CATCH) study. 
CATCH is an observational, prospective “real world” cohort 
of patients with early inflammatory arthritis (EIA) at 15 sites 
recruited since July 2007. Inclusion criteria were age >16 
years, between 6 weeks and 12 months of persistent 
synovitis, and 2 swollen joints or 1 swollen 
metacarpophalangeal or proximal interphalangeal joint with 
1 of the following: positive rheumatoid factor, positive anti-
cyclic citrullinated peptide (anti-CCP), morning stiffness 
>45 minutes, response to nonsteroidal anti-inflammatory 
drugs, or painful metatarsophalangeal squeeze test. The 
majority of CATCH patients were recruited from the high 
population provinces, mainly Ontario and Quebec. All 
patients signed informed consent after reading a letter of 
information that was approved by either a central or 
institutional ethics board. 
 Patients were evaluated at baseline and at subsequent 
visits according to standard protocol. Treatment was left to 
the discretion of the treating physician and, included any 
combination of disease-modifying anti-rheumatic drug 
(DMARD) therapy and corticosteroids (prednisone doses of 
10 mg daily were allowed). Therapy was adjusted at every 
visit with the aim of disease remission, defined as zero 
swollen joints. Virtually all the patients start DMARDs at 
first visit or shortly thereafter except those who decide not to 
(refuse, want to become pregnant, etc) or those with relative 
contraindications such as severe comorbidities or current 
infection. Patients are enrolling ongoing in this incident 
cohort and thus many people have met only one or two 
follow up times and the vast majority have not dropped out 
or been lost to follow up. We analyzed completers at each 
visit. 
Validated Outcome Measures 
 Outcome measures were assessed at each visit (i.e. at 
baseline, 3, 6, 9, 12, 18, and 24 months). The HAQ was 
assessed as a measure of functional limitation. The HAQ has 
been found to be reproducible and validated as a reliable 
measurement for self-assessment [10]. Disease activity was 
assessed using the modified Disease Activity Score 
(DAS28). Previous studies comparing DAS and DAS28 have 
shown that modified 28-joint counts discriminate disease 
activity just as well as more comprehensive joint counts [11]. 
Statistical Analysis 
 We tested differences in measures of RA activity 
(DAS28) and functional impairment (HAQ). Pearson’s 
correlation coefficients were calculated for HAQ and DAS28 
at baseline, then every 3 months for the first year, and every 
6 months in the second year. Both parametric and non-
parametric statistics were calculated to help compare our 
results to previous studies. The data were stratified by patient 
age (65 versus <65 years old), and again in an exploratory 
analysis by RF status (positive versus negative) to determine 
if the relationships were different in early inflammatory 
arthritis. ANOVA was used to determine whether the HAQ 
and DAS28 varied among different groups at different time 
points. Statistical analyses were performed using SPSS 
software, version 18 for Mac (SPSS, Chicago, IL). P values 
less than 0.05 were considered statistically significant. 
Analyses were done for all patients in the cohort and 
repeated for the subset that had 24 months of complete 
follow up. 
Competing Interests 
 The CATCH study was designed by the investigators and 
financially supported by Amgen Canada and Pfizer Canada 
and as of 2011, further support was provided by Hoffmann-
La Roche, United Chemicals of Belgium (UCB) Canada, 
Bristol-Myers Squibb Canada, Abbott Laboratories, and 
Janssen Biotech Inc. (a subsidiary of Johnson & Johnson 
Inc.). The funders did not have any role in the design and 
analysis of this study. 
RESULTS 
 Baseline demographic characteristics and clinical 
information regarding the 1,143 patients in the CATCH  
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cohort are illustrated in Table 1. Overall, the mean age of the 
patients at baseline was 52.2 ± 15.8, of whom 71.2% were 
female. The mean duration of symptoms at study entry was 
6.3 months. Follow up data for patients present at each visit 
was available for 518 patients during the first 12 months and 
214 patients during the entire 24-month period. Mean and 
median values of HAQ and DAS28 for the 214 patients who 
completed 24 months of follow up were similar to 
corresponding visit values for the entire CATCH cohort 
(data not shown). Mean HAQ and DAS28 scores were 
highest at the initial visit (see Fig. 1). Mean HAQ scores 
decreased over time from a baseline of 0.94 to 0.40 at 24 
months. Mean DAS28 scores decreased over time from a 
baseline of 4.53 to 2.29 at 24 months. Both scores decreased 
over time after initiation of therapy indicating both an 
improvement in functional capacity and decreased joint 
inflammation. 
Table 1. Baseline Characteristics of CATCH Study Participants 
 
Characteristic Value 
Age (years), mean ± SD 52.2 ± 15.8 
Female sex, no. (%) 815 (71.2) 
Duration of symptoms (months) ± SD (Range) 6.3 ± 3.7 
HAQ score, mean ± SD  0.94 ± 0.72 
DAS28 score, mean ± SD 4.53 ± 1.99 
RF positive, no. (%) 636 (57.1) 
Anti-CCP positive, no. (%)  424 (60.0) 
Tender joint count (TJC28) ± SD  8.19 ± 6.82 
Swollen joint count (SJC28) ± SD  7.42 ± 6.28 
Fig. (1). Mean HAQ scores (A) and Mean DAS28 scores (B) over time. Outcome measures were assessed at each visit (i.e. at baseline and 
then every 3 months for the first year and every 6 months for the second year). Panels (C) and (D) show Mean HAQ scores over time 
subdivided by age. 
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 The correlations between the HAQ score and the DAS28 
are shown in Table 2. Pearson correlations were significant 
at all measured time intervals (p<0.01). Correlations between 
HAQ and DAS28 varied over time, the strongest occurred at 
the first visit (r=0.53, n=1143), at which point many of the 
patients were still untreated. Strong correlations were again 
noted at 18 months (r=0.57, n=321) and at 24 months 
(r=0.59, n=214). At 6, 9, and 12 months the correlation was 
weaker (r=0.41, 0.30, and 0.40, respectively). The baseline 
correlation between HAQ and DAS28 was significantly 
different than correlations obtained at 3, 6, and 12 months 
(p=0.02, 0.01, and 0.01, respectively), but not statistically 
significantly different from values obtained at 18 and 24 
months (p=0.54 and 0.43, respectively). 
Table 2. Correlations Between HAQ and DAS28 Over Time 
 
Visit  
(Months) 
No. of  
Patients 
Pearson’s  
Correlation  
Coefficient 
P-Value
†
 (Comparison  
to Previous Visit) 
0 1,143 0.53* - 
3 900 0.43* 0.020 
6 725 0.41* 0.812 
9 581 0.30* 0.040 
12 518 0.40* 0.105 
18 321 0.57* 0.017 
24 214 0.59* 0.828 
*Correlations between HAQ and DAS28 are significant at the 0.01 level (2-tailed). 
Note the N decreases as many patients have not achieved long enough follow up. 
† P-values compare correlation coefficient for HAQ and DAS28 at specified visit to 
correlation obtained at preceding visit. 
 
 Patients who were RF+ had consistently higher mean 
HAQ and DAS28 scores throughout the disease course (see 
Fig. 2). The correlation between HAQ and DAS28 was 
statistically significantly stronger with RF+ patients (r=0.63, 
n=636) than RF negative patients (r=0.47, n=477), p=0.0043. 
Age did not change the association between HAQ and 
DAS28. Patients aged 65 years had a slightly weaker 
correlation (r=0.52) overall than younger patients (r=0.55), 
although the result was not statistically significant (p=0.49). 
Over the disease course, HAQ scores in the older age group 
remained consistently elevated in comparison to those for 
younger patients (see Fig. 2). 
DISCUSSION 
 Over a two-year study period of patients with early 
inflammatory arthritis, we found that functional capacity and 
disease activity both improved after initiation of treatment. 
Our findings differ from previous studies that have found 
worsening functional capacity over the course of RA despite 
stable disease activity; however, our follow up was relatively 
short [7]. This finding may reflect improved response to 
therapeutic treatment options that have become available in 
the last decade, as well as more aggressive treatment 
strategies than in older reports. It is difficult to determine if 
the HAQ and DAS relationship that decreases over time is 
due to variability in the response to treatment in addition to 
the variability between subsets such as RF positive and 
negative patients. 
 We have reviewed the literature for previous correlations 
between HAQ and DAS over time and identified studies 
conducted approximately a decade ago looking at more 
advanced rheumatoid arthritis using a Medline search for 
HAQ and DAS and RA and relationship or correlation, and 
reviewing papers that were relevant and their references. Our 
search yielded an inconsistent relationship between 
functional capacity and disease activity with the relationship 
varying over time and between papers (see Table 3). 
 In a nine-year, open, prospective study population of 378 
patients with early RA started in 1985, Welsing, et al. found 
the HAQsability index correlated significantly with DAS 
scores especially prior to the development of permanent joint 
damage [7]. Functional capacity was most influenced by 
disease activity and joint inflammation in early disease, 
permanent joint damage was the predominant factor in more 
advanced disease [7]. Another study suggested that disease 
activity is the major determinant of the HAQ score [8]. 
Although worsening joint destruction contributed to a 
decline in functional capacity over the years, it was never the 
sole determinant of the HAQ score. Likewise, data from the 
TEMPO trial published in 2006 showed that the severity of 
disease activity over 1 year in patients with active RA 
(disease duration 6 months to 20 years) was strongly 
correlated with greater functional disability as measured by 
the HAQ [9]. 
 Most of the patients studied had mild or no significant 
damage as these were early onset but we did not have the 
Xrays scored which is a limitation. A study by Drossaers-
Bakker, et al. found variations to be reflective of changing 
disease activity [8]. 
 In our study, it appears the strongest correlation between 
HAQ and DAS28 in the first year occurred at the initial visit, at 
which point most of the patients were still untreated. Therefore, 
we conclude there is a correlation between functional capacity 
and disease activity that appears to be strongest at disease onset, 
but remains strong over the course of EIA. 
 Stronger correlations between HAQ and DAS28 were 
observed with RF positive patients and with younger 
patients. Rheumatoid factor has previously been shown to be 
predictive of RA development in EIA [12]; it also serves as a 
prognostic marker as its presence is associated with both 
more severe disease and radiographic joint erosions. Because 
RF is a risk factor of joint damage, early control of disease 
activity, particularly in this subset would likely improve 
long-term functional outcome. 
 The lack of correlation between HAQ and DAS28 in older 
patients may be due to factors other than disease activity, 
whereby comorbidities may contribute to impairment of 
functional capacity. Residual functional limitation during 
clinical remission may be attributed to disease-related damage, 
and has been identified as an irreversible component of the 
HAQ in later stages of the disease whereas the component of 
functional limitation affected by active inflammation is 
considered reversible [13]. In contrast with more advanced RA, 
our cohort represented patients with new onset inflammatory 
arthritis whose erosive joint damage was theoretically minimal. 
Maintaining good functional capacity in these patients through 
correction of reversible causes (i.e. control of disease activity) is 
the main goal of treatment. 
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 When interpreting outcome measures such as the HAQ, 
various sources of functional limitation should be considered 
such as normal aging and OA [13]. Combining the HAQ 
with other clinical measures, such as the DAS28 and mTSS 
(i.e. modified total Sharp score, a validated measure of joint 
space narrowing and joint erosion), helps to overcome this 
obstacle and identify the cause of functional disability. 
 Both disease activity and functional impairment are 
related to work disability even at baseline visit in early RA 
[14]. Higher disease activity, older age, female sex, and 
positive rheumatoid factor status have previously been 
shown to be predictors of a worse functional capacity, 
independent of the DAS [7]. 
 Our study has other limitations. The disease duration and 
follow up are relatively short. In addition, the majority of 
patients included in this study have not yet completed two 
years of follow up; however, we have very little missing data 
and a very low drop-out rate and our completers are 
comparable to the entire cohort in their baseline 
characteristics. 
 In conclusion, by studying early inflammatory arthritis, 
we were able to test the stability of the initial correlations of 
HAQ and DAS28. With earlier identification of RA patients, 
validated outcome measures that have been used to monitor 
disease activity and functional limitation in the past can now 
be applied to a patient population at an earlier stage in the 
disease course. The HAQ and DAS28 are important tools to 
monitor disease progression, and both are necessary with 
 
 
Fig. (2). Mean HAQ and DAS28 scores over time subdivided by RF status and age. (A) Mean HAQ scores over time subdivided by RF 
status. (B) Mean DAS28 scores over time subdivided by RF status. (C) Mean HAQ scores over time subdivided by age. (D) Mean DAS28 
scores over time subdivided by age. Outcome measures were assessed at each visit (i.e. at baseline and then every 3 months for the first year 
and every 6 months for the second year). 
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every patient encounter to help elucidate the cause of 
functional impairment in early RA and to provide a clearer 
understanding of overall health status and functional 
outcome in patients with rheumatoid arthritis. 
Table 3. Published Correlations Between HAQ and DAS 
 
Published Study Time  
Period 
Correlation  
Coefficient 
P Value or  
(95% C.I.) 
Prevoo, et al.  
(1995)i 
6-year period 0.38 p < 0.05  
Drossaers-Bakker, et al. 
 (1999)ii 
Baseline 
Year 3 
Year 6 
Year 12 
0.68 
0.51 
0.79 
0.61 
p < 0.001 
p < 0.001 
p < 0.001 
p < 0.001 
Sokka, et al. 
 (2000)iii 
Baseline 0.45 p < 0.001 
Welsing, et al. 
 (2001)iv 
Baseline 
Year 3 
Year 6 
Year 9 
0.40 
0.40 
0.79 
-0.02  
(0.28, 0.51) 
(0.27, 0.51) 
(0.71, 0.85) 
(-0.27, 0.22) 
Van der Heijde, et al.  
(2006)v 
52-week period 0.64 p < 0.0001 
i.Pearson correlation coefficient for 324 patients with recent-onset RA (ACR criteria, 
disease duration < 1 year) from 2 clinics followed for 6 years between 1985 and 1994 
[11]. 
ii.Spearman’s correlation coefficients for 132 female patients, aged 20-50 years at first 
visit, followed in a 12-year prospective cohort of RA patients [8]. 
iii.Spearman’s correlation coefficient for 141 patients with RA (1987 ACR revised 
criteria), median disease duration 11.8 years, minimum of 3 years [15]. 
iv.Pearson correlations were calculated between the HAQ and the DAS for 378 patients 
with recent-onset RA (disease duration < 1 year) in a prospective study started in 1985 
with data collected at 0, 3, 6, and 9 years after study start [7]. 
v.Pearson correlation coefficient: of 682 enrolled patients, 522 completed 52 weeks of 
treatment. Correlation between patient reported health status measures and measures of 
disease activity were calculated over 52 weeks (LOCF analysis) [9]. 
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